NASDAQ: RYZB - RayzeBio, Inc. Common Stock

Altı ay boyunca karlılık: 0%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı RayzeBio, Inc. Common Stock

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında RayzeBio, Inc. Common Stock

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).

daha fazla ayrıntı
It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2023-09-14
ISIN US75525N1072
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://rayzebio.com
Цена ао 62.49
Günlük fiyat değişimi: 0% (62.49)
Haftalık fiyat değişimi: 0% (62.49)
Aylık fiyat değişimi: 0% (62.49)
3 ayda fiyat değişimi: 0% (62.49)
Altı ayda fiyat değişimi: 0% (62.49)
Yıllık fiyat değişimi: 0% (62.49)
Yılbaşından bu yana fiyat değişimi: 0% (62.49)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Toplam: 2.5

Yeterlik

İsim Anlam Seviye
ROA, % 0 0
ROE, % 0 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 953.57 10
karlılık EPS, % 2126.11 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Viking Global Investors, L.P. 6642700 11.09
venBio Partners LLC 5158162 8.61
Versant Venture Management, LLC 5158161 8.61
VR Adviser, LLC 4030471 6.73
Wellington Management Group, LLP 3504409 5.85
Sofinnova Investments, Inc. 2419528 4.04
Orbimed Advisors LLC. 2365213 3.95
Redmile Group, LLC 1857706 3.1
Samsara BioCapital, LLC 1845948 3.08
Blackrock Inc. 1368838 2.28



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Kenneth Song M.D. President, CEO & Director 646k 1975 (50 yıllar)
Mr. Arvind Kush Chief Financial Officer 714.76k 1983 (42 yıl)
Dr. Susan Moran M.D. Chief Medical Officer 559.84k 1969 (56 yıllar)
Mr. Aron Marc Knickerbocker Co-Founder N/A 1969 (56 yıllar)
Mr. Jeff Woodley General Counsel N/A
Mr. Eric Bischoff Senior Vice President of Development & Operations N/A
Dr. Gary G. Li Ph.D. Senior Vice President of Biology & Translational Medicine N/A
Ms. Kimberly Ma M.S. Senior Vice President of Clinical Operations N/A
Dr. Nicholas D. Smith Ph.D. Senior Vice President of Chemistry Innovation N/A
Mr. Abhi Bhat Ph.D. Senior VP of Chemistry & Head of Discovery N/A

Adres: United States, San Diego. CA, 5505 Morehouse Drive - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://rayzebio.com